Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.135 | 0.135 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0036 | 0.5713 | 0.5713 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0011 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0017 | 0.135 | 0.135 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0053 | 0.9472 | 0.9472 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0053 | 0.9472 | 0.9472 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0036 | 0.571 | 0.571 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0017 | 0.135 | 0.135 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.135 | 0.135 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.571 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.9472 | 0.9472 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0017 | 0.135 | 0.135 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0053 | 0.9472 | 0.9472 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0017 | 0.135 | 0.135 |
Echinococcus multilocularis | GPCR, family 2 | 0.0017 | 0.135 | 0.135 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.571 | 0.5 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0017 | 0.135 | 0.135 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.5713 | 0.5713 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.571 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.135 | 0.135 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.571 | 0.571 |
Onchocerca volvulus | 0.0011 | 0 | 0.5 | |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0036 | 0.571 | 0.571 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0017 | 0.135 | 0.135 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0011 | 0 | 0.5 |
Echinococcus granulosus | GPCR family 2 | 0.0017 | 0.135 | 0.135 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0.571 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0017 | 0.135 | 0.135 |
Loa Loa (eye worm) | hypothetical protein | 0.0017 | 0.135 | 0.135 |
Schistosoma mansoni | hypothetical protein | 0.0017 | 0.135 | 0.135 |
Brugia malayi | hypothetical protein | 0.0036 | 0.571 | 0.571 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0036 | 0.571 | 0.571 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0011 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 0.5713 | 0.5713 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.4147 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 8.9125 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.